🚀 VC round data is live in beta, check it out!
Adicet Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Adicet Bio and similar public comparables like Corestemchemon, Annovis Bio, Medivir, MediciNova and more.
Adicet Bio Overview
About Adicet Bio
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Founded
2014
HQ
Employees
152
Website
Sectors
Financials (LTM)
Market Cap
$70M
Adicet Bio Financials
Adicet Bio reported last 12-month revenue of —.
In the same LTM period, Adicet Bio generated — in gross profit and had net loss of ($119M).
Revenue (LTM)
Adicet Bio P&L
In the most recent fiscal year, Adicet Bio reported revenue of — and EBITDA of ($110M).
Adicet Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($110M) | XXX | XXX | XXX |
| Net Profit | ($119M) | XXX | ($117M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Adicet Bio Stock Performance
Adicet Bio has current market cap of $70M.
Market Cap Evolution
Adicet Bio's stock price is $7.31.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $70M | 0.0% | XXX | XXX | XXX | $-12.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAdicet Bio Valuation Multiples
Adicet Bio trades at 0.2x EV/EBITDA.
EV / Revenue (LTM)
Adicet Bio Financial Valuation Multiples
As of March 18, 2026, Adicet Bio has market cap of $70M.
Equity research analysts estimate Adicet Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Adicet Bio has a P/E ratio of (0.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $70M | XXX | $70M | XXX | XXX | XXX |
| EV (current) | ($17M) | XXX | ($17M) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| P/E | (0.6x) | XXX | (0.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Adicet Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Adicet Bio Margins & Growth Rates
Adicet Bio's revenue in the last fiscal year grew by —.
Adicet Bio's revenue per employee in the last FY averaged $0.0M.
Adicet Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (0%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Adicet Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Corestemchemon | XXX | XXX | XXX | XXX | XXX | XXX |
| Annovis Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Medivir | XXX | XXX | XXX | XXX | XXX | XXX |
| MediciNova | XXX | XXX | XXX | XXX | XXX | XXX |
| XBiotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Adicet Bio M&A Activity
Adicet Bio acquired XXX companies to date.
Last acquisition by Adicet Bio was on XXXXXXXX, XXXXX. Adicet Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Adicet Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAdicet Bio Investment Activity
Adicet Bio invested in XXX companies to date.
Adicet Bio made its latest investment on XXXXXXXX, XXXXX. Adicet Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Adicet Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Adicet Bio
| When was Adicet Bio founded? | Adicet Bio was founded in 2014. |
| Where is Adicet Bio headquartered? | Adicet Bio is headquartered in United States. |
| How many employees does Adicet Bio have? | As of today, Adicet Bio has over 152 employees. |
| Who is the CEO of Adicet Bio? | Adicet Bio's CEO is Chen Schor. |
| Is Adicet Bio publicly listed? | Yes, Adicet Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Adicet Bio? | Adicet Bio trades under ACET ticker. |
| When did Adicet Bio go public? | Adicet Bio went public in 2020. |
| Who are competitors of Adicet Bio? | Adicet Bio main competitors are Corestemchemon, Annovis Bio, Medivir, MediciNova. |
| What is the current market cap of Adicet Bio? | Adicet Bio's current market cap is $70M. |
| Is Adicet Bio profitable? | No, Adicet Bio is not profitable. |
| What is the current net income of Adicet Bio? | Adicet Bio's last 12 months net income is ($119M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.